Journal article
Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study
Abstract
BACKGROUND: Pomalidomide-based regimens are the cornerstone of treatment for relapsed/refractory MM (RRMM). Despite the high incidence of chronic kidney disease (CKD) in RRMM, individuals with advanced CKD have been excluded from phase II/III RCTs, creating a gap in our understanding of the effects of pomalidomide use in patients with RRMM complicated with advanced CKD. We undertook a cohort to study to understand the efficacy safety of …
Authors
Meraz-Munoz A; Mian H; Kirkwood D; Jeyakumar N; McCurdy A; Tangri N; Saskin R; Leung N; Wald R; Kitchlu A
Journal
Clinical Lymphoma Myeloma & Leukemia, Vol. 24, No. 11, pp. e861–e869
Publisher
Elsevier
Publication Date
November 2024
DOI
10.1016/j.clml.2024.07.007
ISSN
2152-2650